Strategic Partnerships Psylo's collaborations with prestigious institutions like the University of Sydney and Australia's CSIRO demonstrate a strong focus on innovative research and development in mental health therapies, creating opportunities to offer advanced scientific tools, research services, and clinical trial solutions.

Funding Momentum With recent seed funding rounds totaling over 16 million dollars, Psylo has demonstrated robust investor confidence, indicating a potential market for supporting their ongoing R&D efforts, clinical trials, and eventual product commercialization.

Market Focus Psylo’s focus on developing non-hallucinogenic, fast-acting psychedelic-based psychiatric treatments positions it as a leader in a niche market, encouraging sales opportunities in neuropharmaceuticals and mental health solutions targeting healthcare providers and pharmaceutical companies.

Innovative Technology Using advanced neuroscience combined with computational drug discovery signifies a cutting-edge approach, opening avenues for selling specialized research tools, AI-driven analytics platforms, and collaboration on next-generation therapeutics for biotech and pharma clients.

Growth Potential As a biotech startup with a small but expanding team and international partnerships, Psylo offers opportunities to provide tailored consulting, specialized research equipment, and strategic advisory services to accelerate their development pipeline and market entry strategies.